{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:09:03Z","timestamp":1792674543505,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>No standard of care for older patients with aggressive adult T-cell leukemia\/lymphoma (ATL) has been established. We evaluated the efficacy of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) every 2 weeks with mogamulizumab (Moga; Moga-CHOP-14) for older patients with untreated ATL. In this multicenter phase 2 trial, patients aged \u226566 years and those aged 56 to 65 years ineligible for transplantation received 6 cycles of Moga-CHOP-14, followed by 2 cycles of Moga monotherapy. The primary end point was 1-year progression-free survival (PFS). Secondary end points were the complete response (CR) rate, overall response rate (ORR), overall survival (OS), 1-year event-free survival (EFS), and safety. We also investigated the impact of CC chemokine receptor 4 (CCR4) mutation and Moga-associated cutaneous adverse events (cAEs) on PFS and OS. The study protocol was amended to allow the dosing interval to be extended to 21 days at the physician\u2019s discretion. Among 48 evaluable patients, the 1-year PFS was 36.2% (90% confidence interval, 24.9-47.6), with a median follow-up of 1.6 years. The 1-year OS and EFS were 66.0% and 29.9%, respectively. CR and ORR were 64.6% and 91.7%. No unexpected toxicities were observed. Of 47 patients who received \u22652 cycles of CHOP, 20 (42.6%) received CHOP-14, among whom 12 (25.5%) completed 6 cycles. CCR4 mutation and Moga-associated cAEs were associated with better OS. This study showed that Moga-CHOP significantly improved PFS, although the optimal interval for CHOP remains undetermined. Moga-CHOP is now considered a preferable first-line treatment for this patient population. This trial was registered at https:\/\/jrct.mhlw.go.jp\/en-top as #jRCTs041180130.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027902","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T16:18:23Z","timestamp":1747325903000},"page":"1440-1449","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia\/lymphoma"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-0385","authenticated-orcid":false,"given":"Makoto","family":"Yoshimitsu","sequence":"first","affiliation":[{"name":"1Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-1279","authenticated-orcid":false,"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"},{"name":"4Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-4565","authenticated-orcid":false,"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Imamura General Hospital, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Hidaka","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-2451","authenticated-orcid":false,"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[{"name":"9Division of Medical Oncology, Hematology, and Infectious Diseases, Faculty of Medicine, Fukuoka University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-9751","authenticated-orcid":false,"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-0970","authenticated-orcid":false,"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[{"name":"11Department of Hematology\/Oncology, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Owatari","sequence":"additional","affiliation":[{"name":"12Department of Hematology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Ryang","family":"Koh","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakamura","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-9006","authenticated-orcid":false,"given":"Masahito","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Imamura General Hospital, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Sekine","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9916-4862","authenticated-orcid":false,"given":"Yuma","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"14Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"14Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-0777","authenticated-orcid":false,"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"15Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-497X","authenticated-orcid":false,"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2025091811220444300_bib1","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025091811220444300_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"34","key":"2025091811220444300_bib3","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025091811220444300_bib4","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2025091811220444300_bib5","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1111\/cas.15097","article-title":"Epidemiology of adult T-cell leukemia-lymphoma in Japan: an updated analysis, 2012-2013","volume":"112","author":"Ito","year":"2021","journal-title":"Cancer Sci"},{"issue":"4","key":"2025091811220444300_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428194.2023.2173524","article-title":"A decrease in newly diagnosed patients with adult T-cell leukemia\/lymphoma in Kagoshima, a highly endemic area of HTLV-1 in southwestern Japan","volume":"64","author":"Owatari","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2025091811220444300_bib7","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2025091811220444300_bib8","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci"},{"issue":"5","key":"2025091811220444300_bib9","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025091811220444300_bib10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2025091811220444300_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","article-title":"Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation","volume":"184","author":"Ishida","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"2025091811220444300_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.13220","article-title":"Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma","volume":"102","author":"Ishitsuka","year":"2019","journal-title":"Eur J Haematol"},{"issue":"6","key":"2025091811220444300_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bjh.18281","article-title":"Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma","volume":"198","author":"Shichijo","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"2025091811220444300_bib14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2025091811220444300_bib15","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci"},{"issue":"8","key":"2025091811220444300_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025091811220444300_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.51.1","article-title":"Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma","volume":"51","author":"Yamaguchi","year":"2011","journal-title":"J Clin Exp Hematop"},{"issue":"5","key":"2025091811220444300_bib18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/hon.3072","article-title":"CCR7 alterations associated with inferior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"40","author":"Sakamoto","year":"2022","journal-title":"Hematol Oncol"},{"issue":"14","key":"2025091811220444300_bib19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025091811220444300_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-01-757542","article-title":"Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma","volume":"130","author":"Katsuya","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025091811220444300_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.14634","article-title":"Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma","volume":"181","author":"Tokunaga","year":"2018","journal-title":"Br J Haematol"},{"issue":"13","key":"2025091811220444300_bib21","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J Exp Med"},{"issue":"11","key":"2025091811220444300_bib22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"2025091811220444300_bib23","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2021.280352","article-title":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","volume":"107","author":"Tanaka","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"2025091811220444300_bib24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41375-020-0900-3","article-title":"Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia\/lymphoma and defines an unfavorable indolent subtype","volume":"35","author":"Mar\u00e7ais","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2025091811220444300_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.17749","article-title":"Clinical significance of TP53 mutations in adult T-cell leukemia\/lymphoma","volume":"195","author":"Sakamoto","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2025091811220444300_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.17211","article-title":"Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia\/lymphoma","volume":"192","author":"Sakamoto","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2025091811220444300_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma","volume":"131","author":"Kataoka","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/12\/1440\/2412652\/blood_bld-2024-027902-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/12\/1440\/2412652\/blood_bld-2024-027902-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:23:13Z","timestamp":1758208993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/12\/1440\/537311\/A-phase-2-trial-of-CHOP-with-anti-CCR4-antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,9,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027902","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,18]]},"published":{"date-parts":[[2025,9,18]]}}}